SK Life Science Inc., a subsidiary of South Kore-based SK Biopharmaceuticals Co. Ltd, announced on Thursday that it has received US Food and Drug administration (FDA) approval for the investigational new drug (IND) application to study SKL27969 as a potential treatment for advanced solid tumours.
The company is to carry out a Phase 1/2 open-label, non-randomised, multicentre, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SKL27969 in adult patients with solid tumours.
Marc Kamin, MD, chief medical officer at SK life science, said, 'We look forward to learning more about the potential of SKL27969 as a treatment option for a range of advanced solid tumours. We are excited to expand our R&D efforts into discovering potential new therapies for cancer.'
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma